<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044278</url>
  </required_header>
  <id_info>
    <org_study_id>LAM20007</org_study_id>
    <nct_id>NCT00044278</nct_id>
  </id_info>
  <brief_title>Pediatric Epilepsy Study in Subjects 1-24 Months</brief_title>
  <official_title>An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with
      partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age
      who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will
      be added to the subject's current epilepsy medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The long-term safety of LAMICTAL will be assessed by adverse events, ECGs, vital signs,and laboratory tests.</measure>
    <time_frame>43 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness will be assessed by percent change from baseline in seizure frequency over the course of treatment. Investigators global evaluation of subjects status; standard pharmacokinetics.</measure>
    <time_frame>43 Months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">197</enrollment>
  <condition>Epilepsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for
             LAMICTAL naive subjects as follows:

          -  A confident diagnosis of epilepsy.

          -  4 or more partial seizures per month.

          -  current treatment with 1 or 2 anti-epileptic drugs.

        Exclusion criteria:

          -  Has seizures not related to epilepsy.

          -  Has a surgically implanted and functioning vagal nerve stimulator.

          -  Has previously been treated with lamotrigine.

          -  Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the
             ketogenic diet.

          -  Use of experimental medication within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beirut</city>
        <zip>11072020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1150</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Puerto Rico</country>
    <country>Slovakia</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 14, 2015</lastchanged_date>
  <firstreceived_date>August 23, 2002</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>partial seizures</keyword>
  <keyword>epilepsy</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
